Abstract Background and Aims The burden and outcomes of inflammation in patients with
atherosclerotic cardiovascular disease (ASCVD) are not well defined beyond the controlled …

Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors are widely recognised as
being able to induce a potent reduction in low‑density lipoprotein‑cholesterol. An increasing …

Patients with coronary artery disease (CAD) at low residual inflammatory risk are often
overlooked in research and practice. This study examined the associations between …

Background. Oxidative stress and inflammation are typically implied in atherosclerosis
pathogenesis and progression, especially in coronary artery disease (CAD). Our objective …

Background In patients undergoing percutaneous coronary intervention (PCI), the use of anti-
inflammatory therapy with colchicine is associated with a reduction of recurrent ischemic …

Background High-sensitivity C-reactive protein (hs-CRP) has been proposed as an indicator
of inflammation and cardiovascular risk. However, little is known of the comparative temporal …

US Tantry et al. and inflammatory burden. The authors demonstrated that high perivascular
FAI values (cutoff≥− 70· 1 HU) are an indicator of increased cardiac mortality and can be …

Background To evaluate the relationships between residual inflammatory risk [assessed by
high-sensitivity C-reactive protein (hsCRP)], residual cholesterol risk [assessed by low …

Lipid-lowering therapy is undoubtedly the most essential part of treating atherosclerotic
cardiovascular diseases (CVD). However, even with aggressive lipid-lowering therapy, CVD …

Inflammation contributes to the pathogenesis of coronary heart disease (CHD). Routine
clinical practice includes assessing residual risks of cholesterol and thrombosis in patients …